Analysts Set Expectations for INKT Q1 Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for MiNK Therapeutics in a research note issued on Friday, November 7th. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.90) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q2 2026 earnings at ($1.04) EPS, Q3 2026 earnings at ($0.93) EPS and Q4 2026 earnings at ($1.03) EPS.

MiNK Therapeutics (NASDAQ:INKT) last released its earnings results on Thursday, August 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.51).

A number of other analysts have also recently weighed in on INKT. Weiss Ratings restated a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Wednesday, October 8th. B. Riley raised MiNK Therapeutics to a “strong-buy” rating in a research report on Friday, July 18th. Zacks Research upgraded MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 20th. Finally, Wall Street Zen downgraded MiNK Therapeutics to a “strong sell” rating in a report on Saturday, August 23rd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $37.50.

MiNK Therapeutics Trading Down 0.8%

NASDAQ:INKT opened at $13.66 on Monday. The company has a 50-day moving average of $14.39 and a 200-day moving average of $12.76. The firm has a market cap of $61.74 million, a price-to-earnings ratio of -4.74 and a beta of 0.33. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $76.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.